Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Xspray Pharma AB ( (SE:XSPRAY) ) has issued an update.
Xspray Pharma’s Q3 2025 report highlights significant developments, including achieving bioequivalence for its XS003 product at a reduced dosage compared to the reference drug Tasigna, and securing a license agreement with Handa Therapeutics for commercialization in the US and Asian markets. Additionally, the company raised approximately SEK 161 million through a heavily oversubscribed share issue and extended the maturity of an existing loan, enhancing its financial position.
More about Xspray Pharma AB
Xspray Pharma AB operates in the pharmaceutical industry, focusing on developing improved versions of existing drugs through innovative formulation techniques. The company primarily targets the oncology market, aiming to enhance drug bioavailability and reduce dosage requirements.
Average Trading Volume: 181,359
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.06B
See more insights into XSPRAY stock on TipRanks’ Stock Analysis page.